Wanbury Limited (WANBURY)

Loading page…

Wanbury Limited (WANBURY) · mywealthgrid

About

Wanbury Limited is a pharmaceuticals company in the healthcare sector with a market capitalisation of ₹912.11 Cr. Quarterly revenues are stable around ₹160–172 Cr, and the company trades at a PE of 21.22. It operates as a mid-size player in the Indian pharma industry.

Face value: ₹10

Market cap

₹691 Cr

P/E

16.1×

P/B

10.9×

Dividend yield

ROE

70%

ROCE

36.1%

Debt / equity

2.92

OPM

12.7%

EPS (TTM)

₹13.1

Book value

₹18.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Operating margin volatility: OPM fell from 18.14% (Mar 2026) to 9.8% (Jun 2026), an 830 bps swing, indicating operational instability or cost pressures—verify the cause.
Extreme profit volatility: Net profit collapsed from ₹21.7 Cr (Mar 2026) to ₹3.24 Cr (Jun 2026) on flat revenue, raising concerns about earnings sustainability.
High leverage: D/E of 2.92 amplifies downside risk if operational or market conditions deteriorate.

Generated analysis · source review pending

Growth drivers

Margin recovery: Operating margin was 16–18% through Mar 2026; recovery from the current 9.8% would restore net profit toward ₹26–30 Cr on flat revenue—verify the cause of recent compression.
Revenue growth potential: Quarterly revenue of ₹160–172 Cr suggests an annual base of ₹640–688 Cr; verify whether new products, segments, or geographies could expand this.
ROE sustainability: At 70.01% ROE, continued capital efficiency as margins normalize would accelerate shareholder returns—verify whether capital base and leverage remain stable.

Generated analysis · source review pending

2,527 historical price candles were omitted because the exchange source has not been verified.

₹198.0-8.7%1Y

Quick read

rule-based

Pros

+Strong return on equity of 135.1% (3-yr avg)
+High return on capital employed of 40.7%

Cons

−Profit declined 13.9% a year over the last 5 years
−Heavily leveraged (debt/equity 2.9)
−Weak interest coverage of 1.8×
−Trading at 10.9× book value

Research score

Structured signal from quality, growth, valuation and momentum.

53/100

Business quality: 46
Growth: 55
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	444	374	374	367	393	511	500	576	600
COGS	191	174	174	176	217	300	303	303	294
Gross profit	253	200	200	192	175	211	197	273	305
	234	267	267	168	157	176	174	203	229
	19	-68	-68	23	18	35	23	70	76
OPM %	4.2%	-18.2%	-18.2%	6.4%	4.6%	6.9%	4.6%	12.2%	12.7%
Depreciation	10	10	10	10	10	11	12	13	13
Interest	36	31	31	33	23	21	21	29	37
	90	77	77	84	2	78	0	29	3
Profit before tax	62	-32	-32	65	-12	81	-10	56	30
Tax	0	-0	-0	0	0	-0	0	0	-1
Tax %	0.6%	-1.2%	-1.2%	0.3%	1.6%	-0.4%	1.1%	0.7%	-3.3%
	62	-32	-32	64	-13	81	-10	56	31
PAT margin %	14%	-8.6%	-8.6%	17.5%	-3.2%	15.9%	-2.1%	9.7%	5.1%
EPS (₹)	29.8	-13.5	-13.5	26.9	-5	26.9	-6.2	26.4	9.3
EPS adjusted (₹)	26.7	—	—	25.8	-5	24.9	-3.2	17.1	9.3
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025

₹ Cr	Mar 2016	Mar 2017	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity capital	20	23	25	25	33	33	33	33
Reserves	-221	-217	-168	-181	-56	-66	-5	27
	322	324	124	160	67	64	110	173
	267	288	298	285	309	273	206	181
Total equity & liabilities	388	418	279	289	353	304	343	414
	177	186	164	167	167	152	167	201
CWIP	14	10	14	11	2	2	3	5
Investments	0	0	0	0	0	0	0	0
	197	222	101	111	183	151	174	208
Total assets	388	418	279	289	353	304	343	414

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	53.4%	53.4%	52.2%	44.7%	41.3%	39.4%	47.4%	50.9%
EBITDA margin %	-18.2%	-18.2%	6.4%	4.6%	6.9%	4.6%	12.2%	12.7%
EBIT margin %	-20.9%	-20.9%	3.7%	2.1%	4.7%	2.2%	9.9%	10.5%
PAT margin %	-8.6%	-8.6%	17.5%	-3.2%	15.9%	-2.1%	9.7%	5.1%
Working capital
Receivable days	—	—	50	32	45	50	57	70
Inventory days	—	—	25	42	60	27	43	47
Payable days	—	—	253	225	218	179	196	172
NWC days	—	—	-177	-151	-113	-103	-96	-55
Leverage
Current ratio	—	—	0.29	0.27	0.48	0.38	0.74	1.11
Debt to EBITDA	—	—	5.31	8.91	1.9	2.77	1.57	2.27
Debt to equity	—	—	-0.87	-1.03	-2.86	-1.95	3.93	2.92
Interest coverage	-0	-0	0.5	0.5	1.2	0.5	2.1	1.8
Asset turnover	—	—	1.32	1.36	1.45	1.64	1.68	1.45
Return ratios
Return on assets %	—	—	23.1%	-4.4%	23.1%	-3.4%	16.3%	7.4%
Return on capital employed %	—	—	-46.1%	-16.1%	-351.5%	-70.9%	46.3%	36.1%
Return on equity %	—	—	-44.9%	8.1%	-347.9%	31.7%	200.2%	51.5%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	39.8%	39.79%	39.79%	39.79%	39.77%	39.76%	39.76%	39.63%	43.09%	43.07%	43.02%	43.02%
	0%	0%	0.18%	0.22%	1.02%	0.84%	1.55%	1.59%	0.82%	0.72%	0.59%	0.89%
	0.13%	0.13%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0.06%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	60.07%	60.08%	60.03%	59.99%	59.21%	59.4%	58.69%	58.78%	56.09%	56.21%	56.39%	56.03%
No. of shareholders	—	—	—	—	—	—	—	—	17,717	17,261	16,732	17,174

Promoter holding up 3.22 percentage points since Sep 2023.

30 deals · 29 Oct 2021 – 12 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
12 Aug 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Sell	4,14,005	₹251.38	₹10.41 Cr
12 Aug 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	2,41,998	₹252.40	₹6.11 Cr
11 Aug 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Buy	2,17,468	₹243.49	₹5.30 Cr
11 Aug 2026	HRTI PRIVATE LIMITED	Bulk	NSE	Sell	2,09,192	₹245.28	₹5.13 Cr
14 Jul 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Sell	3,29,561	₹338.14	₹11.14 Cr
14 Jul 2026	JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	NSE	Buy	3,24,712	₹337.78	₹10.97 Cr
14 Jul 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Buy	1,76,345	₹336.68	₹5.94 Cr
14 Jul 2026	NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	NSE	Sell	1,76,345	₹336.91	₹5.94 Cr
14 Jul 2026	GRT STRATEGIC VENTURES LLP	Bulk	NSE	Buy	1,75,309	₹338.33	₹5.93 Cr
14 Jul 2026	GRT STRATEGIC VENTURES LLP	Bulk	NSE	Sell	1,75,309	₹338.66	₹5.94 Cr

1–10 of 30

1 / 3

Mr. CHANDRAN KRISHNAMOORTHYExecutive Director-Chairperson
Mr. MOHAN KUMAR RAYANAExecutive Director
Vinod VermaChief Financial Officer
Ms. ANUPAMA VAIDYANon-Executive - Independent Director
Mr. MRIDUL SUMANLAL MEHTANon-Executive - Independent Director
Mr. MANOJKUMAR KHUBCHAND GURSAHANINon-Executive - Independent Director
Mr. PALLAVUR SANKAR DASS VAIDYANATHANNon-Executive - Independent Director
Jitendra J GandhiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	527	0.01	0.03%	0.002%	+1

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

3

Dividend dividend29 Jul 2010 · ex-date₹1
Dividend dividend12 Mar 2009 · ex-date₹0.5
Final dividend13 Sept 2007 · ex-date₹2

1

Board meeting to consider results11 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

22 announcementsExport CSV

29 Sept 2026, 1:13 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

2 Sept 2026, 3:29 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

31 Aug 2026, 7:02 pmCorp. Action

Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM).

Book Closure PDF

31 Aug 2026, 6:47 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

31 Aug 2026, 6:35 pmAGM/EGM

Annual Report 2025-26 And Notice Of The 38Th Annual General Meeting Of Wanbury Limited.

AGM PDF

28 Aug 2026, 1:40 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

11 Aug 2026, 9:14 pmCompany Update

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of ESOP / ESPS PDF

11 Aug 2026, 9:10 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

Date	Category	Subject	Filing
29 Sept 2026, 1:13 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
2 Sept 2026, 3:29 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication

Loading announcements…

Ratio	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	53.4%	53.4%	52.2%	44.7%	41.3%	39.4%	47.4%	50.9%
EBITDA margin %	-18.2%	-18.2%	6.4%	4.6%	6.9%	4.6%	12.2%	12.7%
EBIT margin %	-20.9%	-20.9%	3.7%	2.1%	4.7%	2.2%	9.9%	10.5%
PAT margin %	-8.6%	-8.6%	17.5%	-3.2%	15.9%	-2.1%	9.7%	5.1%
Working capital
Receivable days	—	—	50	32	45	50	57	70
Inventory days	—	—	25	42	60	27	43	47
Payable days	—	—	253	225	218	179	196	172
NWC days	—	—	-177	-151	-113	-103	-96	-55
Leverage
Current ratio	—	—	0.29	0.27	0.48	0.38	0.74	1.11
Debt to EBITDA	—	—	5.31	8.91	1.9	2.77	1.57	2.27
Debt to equity	—	—	-0.87	-1.03	-2.86	-1.95	3.93	2.92
Interest coverage	-0	-0	0.5	0.5	1.2	0.5	2.1	1.8
Asset turnover	—	—	1.32	1.36	1.45	1.64	1.68	1.45
Return ratios
Return on assets %	—	—	23.1%	-4.4%	23.1%	-3.4%	16.3%	7.4%
Return on capital employed %	—	—	-46.1%	-16.1%	-351.5%	-70.9%	46.3%	36.1%
Return on equity %	—	—	-44.9%	8.1%	-347.9%	31.7%	200.2%	51.5%

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	43	43	32	30	44	17	38	20	4	26
	-20	-13	-1	-3	64	8	1	-9	-17	-51
	-28	-27	-33	-27	-108	-17	-26	-32	15	26
Net cash flow	-5	3	-2	-0	-0	7	13	-21	2	1
Free cash flow	—	—	—	—	36	17	38	20	-13	-23
CFO / Operating profit %	—	234.2%	—	—	188.3%	92.6%	106.3%	85.5%	5.7%	34.2%

Wanbury Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

3

1

Announcements

Not in the F&O segment

3

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Wanbury Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Events

Dividends3

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

Dividends3

Board meetings1

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

1

3

1